TRAF6 and diffuse large B-cell lymphoma: Rigosertib, a multikinase inhibitor, has selective cytotoxicity to diffuse large B cell lymphoma, which is related to its ability to reduce the expression of unmodified and sulfonated TRAF6 and inhibit the nuclear entry of TRAF6 [140].